MICHAEL JOSEPH POIESZ M.D. NPI 1952528762

NPI Details

Michael Joseph Poiesz, M.D. is a hematology and oncology internal medicine in Pensacola, FL with 21 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Michael Joseph Poiesz, M.D. NPI is 1952528762. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4724 N DAVIS HWY
PENSACOLA, FL
ZIP 32503-339
Phone: (850) 696-4000
Fax: (850) 434-2647

The NPI 1952528762 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gadobenate dimeglumine (multihance), per ml (HCPCS:A9577)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Blood creatinine level (HCPCS:82565)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Ct scan of chest with contrast (HCPCS:71260)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ct scan of chest without contrast (HCPCS:71250)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) (HCPCS:G0279)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Collection of blood sample from implanted device (HCPCS:36591)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Diagnostic mammography of both breasts (HCPCS:77066)
• Diagnostic mammography of 1 breast (HCPCS:77065)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)

The enumeration date for this NPI number is 4/20/2007 and was last updated on 11/14/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.